Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Description

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Study Start Date

October, 20 2017

Estimated Completion Date

July 2019

Interventions

No interventions cited

Study ID

Hope Pharmaceuticals -- ST-003

Status

Recruiting

Trial ID

NCT03319914

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

111

Sponsor

Hope Pharmaceuticals

Inclusion Criteria

  • Previously enrolled as a patient in ST-001 CALISTA study
  • Willing to provide written informed consent
  • Willing and able to adhere to all study-related procedures
  • Willing to authorize release of medical records
  • Willing to authorize collection of medical data from health care providers
  • Provide email, home address and phone number where he/she can be reached

Exclusion Criteria

    • Patient did not participate in ST-001 CALISTA study

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (5)

Study Location Distance Name Phone Email
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Sagar Nigwekar MD None None
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Sagar Nigwekar MD None None
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Sagar Nigwekar MD None None
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Sagar Nigwekar MD None None
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Sagar Nigwekar MD None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.